登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
ClinicalTrials.gov 上登记的一项肌萎缩侧索硬化症开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06671236,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Serum creatinine less than or equal to 2.0 mg/dL;
入选标准第 6 条
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal;
入选标准第 7 条
Bilirubin < 1.5 (except Gilbert's disease);
入选标准第 8 条
Seropositive for HIV, hepatitis B or hepatitis C;
排除标准第 6 条
Pregnant or lactating patients;
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06671236,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female patients aged 18 to 70 years; According to current international diagnostic criteria: If there is a stable dose for more than one month prior to study entry. For example, patients with ALS can continue treatment with riluzole (Rilutek®) and/or edaravone (Radicava®); Patients must have > two weeks after the end of major surgery and after the completion of participation in other research trials; Patients must have recovered from clinical toxicity (CTCAE [5th Edition] toxicity values have resolved to < 2); Serum creatinine less than or equal to 2.0 mg/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal; Bilirubin < 1.5 (except Gilbert's disease); Lung slow vital capacity (SVC) > 70% of predicted normal; No history of abnormal bleeding tendency; Informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care.排除标准:Exclusion Criteria:
uncontrolled infection; < 3 drugs do not adequately control hypertension; Documented history of pulmonary embolism within 6 months of enrollment; Clinically significant cardiology, defined as: myocardial infarction, NYHA-graded class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment; Patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis; Seropositive for HIV, hepatitis B or hepatitis C; Pregnant or lactating patients; Patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception; Participation in any other interventional study; Treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. Patient participation in observational/non-interventional clinical studies will be discussed with the Medical Monitor; Prior treatment with ALS gene or cell therapy; History of clinically significant tumor, liver or kidney disease, or other uncontrolled disease; presence of a feeding tube; Current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-Bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs; Subjects who, in the opinion of the investigator, are at significant risk of suicide; Other conditions that the investigator considers unsuitable for enrollment.
引自 ClinicalTrials.gov, NCT06671236, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06671236,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。